KHẢO SÁT NỒNG ĐỘ BETA-CROSSLAPS Ở BỆNH NHÂN ĐAU XƯƠNG KHỚP TẠI BỆNH VIỆN STO-PHƯƠNG ĐÔNG

Abstract

Objective: Assessment of Beta-Crosslaps levels in patients with joint pain symptoms, their associations, and the role of Beta-Crosslaps in the diagnosis and management of bone and joint disorders. Study Subjects and Methods: The study included 1,290 individuals who visited STO Phuong Dong Hospital from February 15, 2022, to December 30, 2024. Participants were divided into two main groups:Control group: 609 healthy individuals without symptoms of bone or joint diseases, Disease group: 681 patients presenting with symptoms of bone and joint pain. Study design: A cross-sectional descriptive study. Data collection included age, gender, and bone and joint pain status. Beta-Crosslaps  levels were quantified using the Cobas 411 automated immunoassay analyzer with reagents, calibrators, and controls from Roche Diagnostics. Statistical analysis was performed using STATA 14.0. Mean Beta-Crosslaps  values between age groups and genders were compared using the t-test and one-way ANOVA for independent and normally distributed groups. Results: Beta-Crosslaps levels increased with age in both males and females across the control and disease groups. However, no statistically significant difference was observed between the age groups 50–70 and >70. In the control group, Beta-Crosslaps  levels were higher in males than females across all age groups, except for the >70 age group, where the difference was not statistically significant.In the disease group, males had higher Beta-Crosslaps levels than females in the <50 age group, whereas females had higher levels than males in the 50–70 and >70 age groups. Within the same gender and age group, patients in the disease group had higher Beta-Crosslaps  levels than those in the control group. Conclusion: A retrospective preliminary study on Beta-Crosslaps levels in patients with joint pain revealed that Beta-Crosslaps levels increase with age and are elevated in patients with joint pain. These patients exhibit an enhanced bone resorption process, which increases the risk of osteoporosis. Therefore, preventative treatment for osteoporosis should be considered for these individuals. Further research is needed to explore the variations in Beta-Crosslaps  levels across different bone and joint diseases.